menu search

Biocryst selects er-kim pharmaceuticals as commercial partner for orladeyo® (berotralstat) in turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...

July 19, 2023, 11:00 am

Kalvista (kalv) surges 15% on update from angioedema study

KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angi...

July 10, 2023, 11:00 am

Regeneron's high-dose eylea not approved by fda

Regeneron Pharmaceuticals Inc. REGN, -1.34% said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the biologic...

June 27, 2023, 3:02 pm

Why shares of pharvaris n.v. are up tuesday

Pharvaris has only one drug, deucrictibant, in its pipeline. Deucrictibant is being examined to treat hereditary angio...

June 27, 2023, 12:11 pm

Intellia (ntla) up on positive data updates from hae study

Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema....

June 12, 2023, 11:43 am

Why is intellia (ntla) stock up 5% today?

Intellia (NASDAQ: NTLA ) is trending on social media, and NTLA stock is up over 5% today after the drugmaker reported new, positive results from one o...

June 12, 2023, 10:07 am

Intellia therapeutics announces new positive clinical data from phase 1 study of ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioedema (hae)

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angio...

June 11, 2023, 12:30 pm

Oculis could have a breakthrough treatment on its hands with an eye drop for dme

Oculis is an “under-the-radar” biotech stock that is off to a strong start thanks to a lead drug candidate that could offer hope for diabetic macu...

June 9, 2023, 3:02 pm

Intellia therapeutics to present updated interim data from ongoing phase 1/2 study of ntla-2002 for the treatment of hereditary angioedema (hae) at the eaaci hybrid congress 2023

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the st...

May 31, 2023, 11:30 am

Biocryst to present new orladeyo® (berotralstat) data at 2023 european academy of allergy and clinical immunology congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will prese...

May 31, 2023, 7:02 am

Alimera (alim) completes enrollment in eye disease study

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular e...

May 25, 2023, 11:17 am

Tactile systems: lymphedema, afflovest markets continue adding value

Tactile Systems has outstripped peers with a tremendous rally starting in November last year. The market has no doubt increased its expectations for t...

May 25, 2023, 1:18 am

Alti global, inc. (alti) q1 2023 earnings call transcript

AlTi Global, Inc. (NASDAQ:ALTI ) Q1 2023 Earnings Conference Call May 22, 2023 5:00 PM ET Company Participants Lily Arteaga - Head of Investor Relatio...

May 22, 2023, 7:28 pm

Nu holdings ltd. (nu) q1 2023 earnings call transcript

Nu Holdings Ltd. (NYSE:NU ) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Jorg Friedemann - Investor Relations David V...

May 15, 2023, 11:44 pm

Astria therapeutics to present star-0215 at the 13th c1-inhibitor deficiency and angioedema workshop

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary ang...

April 28, 2023, 8:00 am

Kalvista pharmaceuticals to present data at the 13th c1-inhibitor deficiency & angioedema workshop

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa...

April 27, 2023, 6:30 am

Kodiak (kod) treats first patient in diabetic macular edema study

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases....

April 4, 2023, 2:28 pm

Intellia's (ntla) hae therapy granted rmat by the fda

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the...

March 22, 2023, 9:57 am

Intellia therapeutics: progressing pipeline signals positive outlook for investors

With multiple promising candidates in its pipeline, Intellia is well-positioned to capitalize on the growing demand for gene editing therapies. The re...

March 7, 2023, 9:06 pm

Intellia's stock jumps as crispr therapy moves into phase 2 clinical trial

Shares of Intellia Therapeutics Inc. NTLA, +1.44% rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administ...

March 2, 2023, 8:09 am


Search within

Pages Search Results: